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Prior studies have established that the Cryptococcus neoformans capsular polysaccharide component galac-
toxylomannan (GalXM) manifests serotype-related structural differences that translate into antigenic differ-
ences. We analyzed GalXM from acapsular serotype A and D strains by carbohydrate analysis and static and
dynamic light scattering to determine mass, effective diameter, polydispersity, and diffusion coefficients.
Multiangle laser light scattering showed that GalXM from C. neoformans var. grubii strain cap59 (serotype A)
had larger molecular mass (4.21 106 0.95 106 g/mol) and radius of gyration (207 27 nm) than GalXM
from C. neoformans var. neoformans cap67 (serotype D). cap67 GalXM had corresponding values of 0.70 
106  0.05  106 g/mol and 120  22 nm, respectively. The effective diameter for GalXM and polydispersity
from the two strains varied depending on temperature and medium growth conditions, indicating that GalXM
structure can vary within a strain, depending on its environment. Zeta potential determinations were negative
for GalXM from both strains under all conditions, consistent with the recently reported presence of glucuronic
acid. These results imply that C. neoformans GalXM, like glucuronoxylomannan, can manifest variety- and
growth condition-related variations. Analysis of 16 C. neoformans and 7 Cryptococcus gattii strains with poly-
clonal antibody to a GalXM strain revealed antigenic similarities among the C. neoformans variety neoformans
and grubii strains and no reactivity with C. gattii. As a result of the deleterious effects of GalXM on immune
function, structural and antigenic variability between serotypes may translate into differences in immuno-
modulatory effects.
The encapsulated fungal pathogen Cryptococcus neoformans
causes disease primarily in individuals with impaired immunity
(22). Cryptococcosis is relatively common in individuals with
late-stage human immunodeficiency virus or certain cancers
and in organ transplant recipients (22, 25, 31). C. neoformans
has several well-defined virulence factors that include a poly-
saccharide (PS) capsule (23, 31). The capsular polysaccharide
was classically defined as being composed of glucuronoxylo-
mannan (GXM), galactoxylomannan (GalXM), and manno-
proteins (MP) (19, 24, 29). However, this composition was
inferred based on analysis of culture-shed exopolysaccharide
(6, 18). Recent studies suggest that the capsule is made of
GXM while GalXM and mannoproteins appear to be primarily
export products (10, 17).
GXM has been extensively studied, but considerably less is
known about GalXM (5, 6). Earlier structural studies of
GalXM revealed that GalXM constitutes about 8% of the shed
polysaccharide found in cryptococcal culture supernatants (1,
29) and has an -1,6-galactan backbone containing four poten-
tial short oligosaccharide branch structures. The branches are
3-O-linked to the backbone and consist of an -1,3-mannose,
-1,4-mannose, and -galactosidase trisaccharide with variable
amounts of -1,2- or -1,3-xylose side groups (1, 21, 29). The
GalXM backbone consists of galactopyranose and a small
amount of galactofuranose (29), unlike GXM, which contains
only mannopyranose (1). Recently, it was found that the resi-
due that is (133)-linked to the side chain galactose of GalXM
is -D-glucuronic acid, instead of -D-xylose as previously de-
termined. It was proposed that the GalXM polymer be re-
named to “glucuronoxylomannogalactan” (GXMGal) due to
the presence of glucuronic acid (16). Heiss et al. suggest that
the nomenclature accurately represents both the polymer com-
position and structure (16). Although we agree that GXMGal
is a better term for this polysaccharide based on the existing
information, we will continue to use GalXM for now to main-
tain the continuity of the literature. It is conceivable that as
structural knowledge accumulates, additional revisions to the
nomenclature will be needed in the future. The latter concern
is heightened by data presented in the manuscript showing
considerable variability in GalXM structure under different
conditions. Several recent studies indicate that GalXM is a
potent immunomodulator with pleiotropic deleterious effects
on the immune system (2, 9, 26, 30).
Studies with GalXM from cap67 revealed an average mass
of 1  105 Da (1, 21), which was significantly smaller than that
of GXM (1.7  106 Da) (21). Since GalXM has a smaller
molecular mass, GalXM is the most numerous component
among shed capsular polysaccharide fractions on a molar basis,
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with 2 to 3.5 mol of GalXM for each mole of GXM (21).
Recently, we showed that GalXM is primarily an exopolysac-
charide and that there are serotype-related structural differ-
ences in GalXM, based on nuclear magnetic resonance (NMR)
analysis, that could translate into antigenic variability (10).
Here, we follow up on that lead using carbohydrate analysis,
light scattering, and zeta potential measurements to show that
there are strain- and serotype-related differences in GalXM
structure that could be enhanced by growth conditions.
(The data in this paper are from a thesis submitted by M. De
Jesus (Ph.D. awarded in June 2009) and S.-K. Chow in partial
fulfillment of the requirements for a Ph.D. from the Albert
Einstein College of Medicine, Yeshiva University, Bronx, NY.)
MATERIALS AND METHODS
C. neoformans strains. C. neoformans var. grubii acapsular mutant cap59 was
derived from strain H99 (MAT and hygromycin resistant; serotype A) and was
a kind gift of Joseph Heitman at Duke University. C. neoformans var. neoformans
acapsular mutant cap67 was derived from strain B3501 (serotype D) and was
obtained from the American Type Culture Collection (Manassas, VA). cap67 is
also known in the literature as B-4131, and its capsular phenotype in this strain
can be restored by the CAP59 gene (3). Hence, cap59 and cap67 are derived
from serotype A and D strains that are both complemented with the same gene,
which appears to function in capsular polysaccharide export (15). In the immu-
nofluorescence studies, eight C. neoformans var. grubii (serotype A), eight C.
neoformans var. neoformans (serotype D), and seven C. gattii (serotype B and C)
strains were used. H99 (serotype A) was obtained from the New York State
Herbarium, Albany, NY, and the rest of the serotype A isolates were obtained
from cryptococcal meningitis patients from New York City hospitals (28). Strains
24067, B3501, and Jec21 and five other clinical isolates were used in the serotype
D group. The C. gattii strains included NIH isolates 18, 34, 112, 191, 444, 1343,
and 3939. These isolates have been described previously (4).
GalXM isolation. GalXM was isolated as previously described (10). Briefly, a
400-ml culture of a C. neoformans acapsular mutant of strain cap67 or cap59 was
grown under one of the following conditions: peptone medium supplemented
with 2% galactose, minimal medium (15 mM glucose, 10 mM MgSO4, 29.4 mM
KH2PO4, 13 mM glycine, and 3 M thiamine-HCl; pH 5.5), yeast extract-
peptone-dextrose (YPD; Difco Laboratories, Detroit, MI), or Sabouraud’s dex-
trose broth (Difco Laboratories, Detroit, MI) for 7 days. For the experiments to
evaluate the effect of temperature, C. neoformans was grown in peptone supple-
mented with 2% galactose at 25, 30, 37, or 40°C for 7 days. The culture super-
natant was separated from the cells by centrifugation at 900  g for 15 min at
room temperature and then concentrated using an Amicon centrifugal filter with
a 10,000-molecular-weight (MW)cutoff (Millipore, Bedford, MA). The material
was then dialyzed for 1 week against distilled water, and the 10-kDa retentate,
containing GalXM and mannoproteins, was passed through a 0.2-m-pore-size
filter. The resulting filtrate was then lyophilized and stored at room temperature.
The freeze-dried mixture was dissolved in 25 ml of start buffer [0.01 M Tris base
and 0.5 M NaCl solution, pH 7.2, to which CaCl2 and Mn(II)Cl2 was sequentially
added to final concentrations of 1 mM]. To separate the GalXM and manno-
proteins, the solution was then continuously passed through a concanavalin
A-Sepharose 4B column (2.5 by 10 cm) (Sigma) for 16 h at 4°C using a peristaltic
pump with a flow rate of 16 ml/h. The flowthrough as well as five column washes
with start buffer were collected as 25-ml fractions (21). To identify carbohydrate-
containing fractions, we tested these using a phenol-sulfuric acid assay (11). The
fractions were combined, concentrated by ultrafiltration, and dialyzed against
water for 3 days. GalXM was then recovered by lyophilization.
GalXM glycosyl composition analysis. GalXM samples were dissolved in
methanol–1 M HCl and incubated at 80°C for 18 h. Methanolyzed samples were
then per-O-trimethylsilylated by treatment with Tri-Sil (Pierce) for 30 min at
80°C. The per-O-trimethylsilyl (TMS) derivatives were analyzed by gas chroma-
tography coupled to mass spectrometry (GC-MS). The derivatized structures
were first separated on an HP 5890 gas chromatograph using a Supelco DB-1
fused silica capillary column (30 m by 0.25-mm internal diameter). Peaks de-
tected by GC were fragmented in a 5970 MSD mass spectrometer, interfaced to
the gas chromatograph. Carbohydrate standards included arabinose, rhamnose,
fucose, xylose, glucuronic acid, galacturonic acid, mannose, galactose, glucose,
mannitol, dulcitol, and sorbitol.
Molecular mass determination. Molecular masses were determined and cal-
culated by multiangle laser light scattering as described by McFadden et al. and
Frases et al. (12, 13, 21).
Zeta potential measurements. Zeta potential (), particle mobility, and shift
frequency of polysaccharide samples were calculated in a zeta potential analyzer
(ZetaPlus; Brookhaven Instruments Corp., Holtsville, NY). Zeta is a measure-
ment of charge (in millivolts) defined as the potential gradient that develops
across the interface between a boundary liquid in contact with a solid and the
TABLE 1. Glycosyl composition analysis
Strain and
component
Composition under the indicated condition (mol%)a
Temp Mediumb
25°C 30°C 37°C 40°C Minimal Sab YPD Pep-Gal
cap67
Xyl 10.8 14.1 5.0 14.5 NA 13.8 15.8 13.0
GlcA 1.2 2.0 2.3 3.3 NA
GalA NA
Man 38.9 33.5 51.3 30.9 NA 24.5 27.7 24.8
Gal 44.8 48.9 35.2 50.1 NA 56.8 49.5 57.7
Glc 3.7 1.0 3.9 1.0 NA 4.8 7.0 4.4
cap59
Xyl 6.1 7.2 10.7 9.2 15.8 13.9 13.3 10.5
GlcA 3.3 3.1 3.1 1.9
GalA
Man 37.5 28.9 31.0 32.3 25.8 25.6 31.0 16.1
Gal 52.6 58.8 53.8 54.2 54.2 58.7 53.0 69.5
Glc 3.7 1.1 1.3 1.3 2.3 1.8 2.7 3.8
a NA, data were not available due to low sample recovery.
b Sab, Sabouraud’s broth; Pep-Gal, peptone supplemented with galactose.
TABLE 2. GalXM molecular properties calculated by multiangle
laser light scattering in a molecular weight analyzer
GalXM
source
Refractive index
(dn/dc at
620 nm)
Mw (106
g/mol) Rg (nm)
Mw/Rg
(103)a
A2 (103
cm3 mol/2
cap59 0.1923 4.21 	 0.95 207 	 27 20.34 0.26 	 0.12
cap67 0.1982 0.70 	 0.05 120 	 22 5.83 4.20 	 3.60
a Mass density.
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mobile diffuse layer in the body of the liquid. Derivation of zeta potential is
described in Frases et al. (12).
GalXM particle sizes. The effective diameter and the polydispersity of GalXM
preparations were measured by quasi-electric light scattering (QELS) or mul-
tiangle laser light scattering in a 90Plus/BI-MAS Multi-Angle Particle Sizing
analyzer (Brookhaven Instruments Corp., Holtsville, NY). The protocol used to
measure particle size is described in Frases et al. (12, 13). Both GalXM samples
were analyzed under the same conditions.
Immunofluorescence. Sixteen C. neoformans strains (eight each of serotypes A
and D, respectively) and seven C. gattii strains (three of serotype B and four of
serotype C) were grown in Sabouraud dextrose broth (Difco Laboratories, De-
troit, MI) for 1 day at 30°C. The cells were then transferred to capsule-inducing
medium (1:10 Sabouraud broth-morpholinepropanesulfonic acid [MOPS], 50
mM, pH 7.3) for another day of incubation at 30°C. In the experiment associated
with the growth curve study, the strains were grown in 1:1 Sabouraud broth–50
mM MOPS, pH 7.3, to optimize cell growth and capsule induction. The cells
were washed three times with phosphate-buffered saline (PBS; pH 7.4) and
counted with a hemocytometer. For GalXM staining using GalXM-PA (where
PA is protective antigen) polyclonal serum (10), 2  106 cells in 100 l of
immunofluorescence buffer (1% bovine serum albumin [BSA] and 0.05% goat
serum in PBS) were incubated with 4 l of serum for 1 h at room temperature.
Cells were washed three times with buffer and incubated with a 1:25 dilution of
goat anti-rat IgM-fluorescein isothiocyanate (FITC) as the secondary antibody
for 1 h at room temperature. Cells were then washed and incubated with 1:10,000
Uvitex 2B (Polysciences Inc.) in PBS for 20 min. Stained cells were suspended in
mounting medium (50% glycerol and 50 mM N-propyl gallate in PBS) and
imaged by epifluorescence microscopy on a Zeiss Axioskop 200 inverted micro-
scope equipped with a cool charge-coupled device using a 63, 1.4-numerical
aperture (NA) objective with a 1.6 optovar. Images were acquired using the
same exposure times and microscopic settings and processed by Axio Vision,
version 4.6, software (Carl Zeiss Micro Imaging, New York, NY).
Quantification of GalXM labeling. Fifteen randomly selected fields of view
were imaged for each strain. The cells were stained with Uvitex 2B, and the
images were focused on the plane of the cell wall to avoid bias in locating GalXM
staining. The total number of cells and the number of GalXM-labeled cells in the
field of view were recorded digitally and counted, and the percentage of labeled
cells was calculated in each strain. To study the GalXM staining pattern with
polyclonal antibody, the number of discrete fluorescent signals on the capsule
(expressed in dots) was counted on each labeled cell and categorized into four
groups (1 to 5, 6 to 10, 11 to 15, and 
15 dots) (see Fig. 7). This method did not
count all the fluorescent signals on the labeled cell but was limited to those
signals on the equatorial plane defined by focusing the microscope on the cell
wall. In the experiment associated with the growth curve study, optical density
was read at 620 nm for 2.5 days with six time points (0, 12, 24, 36, 48, and 60 h).
At each interval except 0 h, cells were stained as described above and imaged
using the same microscope setting. Thirty randomly selected fields of view were
imaged followed by GalXM staining quantification.
Statistical analysis. Statistical and computation analyses of light scattering
measurements were carried out with Bi-ZPMwA Zimm Plot software
(Brookhaven Instruments Corp., Holtsville, NY) to calculate Mw, radius of gy-
ration (Rg) and the second virial coefficient (A2). The software 90Plus/BI-MAS
was used for effective diameter, polydispersity, and diffusion coefficient param-
eters (Brookhaven Instruments Corp., Holtsville, NY). For each sample we
isolated two different preparations of GalXM per condition. We then examined
each polysaccharide preparation per condition and took 10 measurements for
each sample. Error was calculated from 10 measurements of one sample. Zeta
Plus software was used for zeta potential, mobility, and frequency shift data
(Brookhaven Instruments Corp., Holtsville, NY). Student’s t test was used in the
immunofluorescence study comparing serotypes A and D.
RESULTS
Glycosyl composition. GalXM samples were subjected to
acidic methanolysis, and their monosaccharide constituents
were analyzed by gas chromatography. This analysis allows the
potential detection of four different forms for each sugar de-
rivative, corresponding to the - and -forms of furanose and
pyranose rings. In association with mass spectrometry analysis,
each peak can be identified precisely, based on the profile of
fragmentation observed. Fragmentation of TMS derivatives of
hexoses usually generates diagnostic peaks at m/z 217 and 214.
Pyranose rings give rise to a ratio of (m/z 204)/(m/z 217) of 
1,
whereas the ratio of furanose rings is 1. Peaks with retention
times corresponding to standard derivatives of the typical cryp-
tococcal GalXM components, mannose (Man), xylose (Xyl),
galactose (Gal), and glucuronic acid (GlcA) were detected in
the hydrolysates. For GalXM samples, Gal was the major
monosaccharide constituent, followed by Man and Xyl. Pro-
portions of monosaccharide constituents were similar in cap59
FIG. 1. Growth temperature and medium dependence of zeta potential measurements. (Top) Zeta potential measurements in mV for GalXM
from strains cap59 and cap67 grown in different media: YPD medium, minimal medium, Sabouraud’s dextrose broth (Sab), and peptone medium
supplemented with 2% galactose. (Bottom) Zeta potential measurements in mV for strains cap59 and cap67 grown at different temperatures.
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and cap67 GalXMs, which presented Gal/Man/Xyl average
molar ratios of 3.5:1.2:1 and 3.2:1.6:1, respectively (Table 1).
GlcA was present in most of the GalXM samples derived from
growing cultures at different temperatures, with an average
molar ratio of 2.2%. Glucuronic acid was not present under all
medium conditions tested. N-Acetyl galactosamine was the
only sugar other than Man, Gal, and Xyl detected in the cap59,
with a molar ratio of 3.6% (data not shown). The method used
FIG. 2. Effective diameter and multimodal size distribution of GalXM from strains cap59 and cap67 grown in YPD medium, minimal medium,
Sabouraud’s dextrose broth (Sab), and peptone medium supplemented with 2% galactose. Effective diameter of GalXM from cap67 in minimal
medium could not be determined due to poor polysaccharide yields. The x axis represents the diameter size distribution of the GalXM particles
measured in nanometers. The y axis corresponds to the percent intensity of weighted sizes (14). Note that there is no panel for GalXM from cap67
grown in minimal medium because we were unable to recover sufficient polysaccharide for this type of analysis in those conditions.
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significantly underestimates glucuronic content, and these
numbers should be considered in light of this fact.
Average molecular mass, radius of gyration, and second
virial coefficients of GalXM samples. Multiangle laser light
scattering was used to determine the average molecular mass
(Mw) of GalXM from cap59 and cap67 acapsular mutants. The
masses of the different GalXM preparations were calculated
from Zimm plots (Table 2). The mass for GalXM for cap59
was about 8-fold greater than that for cap67 (Table 2). The
radius of gyration (Rg) and the second virial coefficient (A2)
FIG. 3. Effective diameter and multimodal size distribution of GalXM from strains cap59 and cap67 grown in peptone supplemented with 2%
galactose at 25°C, 30°C, 37°C, and 40°C. The x axis represents the diameter size distribution of the GalXM particles measured in nanometers. The
y axis corresponds to the percent intensity of weighted sizes (14).
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were also calculated from the light scattering data (Table 2).
The Rg can be described as the average distance from the
center point of PS to the outer edge of the molecule (average
measure of the molecular size). The Rg for the different
GalXM samples manifested significant differences, with 207
nm and 120 nm for cap59 and cap67, respectively. The Rg was
used in conjunction with the Mw to calculate the mass density
of each GalXM sample. This analysis revealed that cap59
GalXM was 4-fold denser than the GalXM obtained from
cap67 (Table 2). The second virial coefficient (A2) is a property
which describes the interaction strength between the molecule
and a solvent, hence giving insights into the tendency of PS
aggregation in that solvent. A2 measurements for the different
GalXM samples showed important differences. GalXM PS pu-
rified from the cap59 mutant was 0.26  103 	 0.12  103
cm3 mol/g2, suggesting higher molecule-solvent interaction
strengths than PS isolated from cap67, which manifested a
negative A2 value (4.20  10
3 	 3.6  103 cm3 mol/g2),
suggesting that molecule-solvent interaction strengths in cap67
are much lower than the molecule-molecule interaction
strengths, resulting in a higher tendency for PS aggregation.
Zeta potential, mobility, and frequency shift. Zeta potential
was determined for GalXM preparations from both cap67 and
cap59 under different medium conditions and temperatures.
For strain cap59 the zeta potentials were 13.40 	 0.88 mV
(mean 	 standard error of the mean [SEM]) in minimal me-
dium, 8.04 	 0.96 mV in Sabouraud’s broth, 13.09 	 3.34
mV in peptone supplemented with galactose, and7.67	 0.26
mV in YPD medium. For cap67 the zeta potential values were
10.39 	 0.44 mV in minimal medium, 5.75 	 0.28 mV in
Sabouraud’s broth, 15.51 mV in peptone supplemented with
galactose, and 5.97 	 0.85 mV in YPD medium. These re-
sults suggest that the cryptococcal growth medium can affect
the zeta potential of the GalXM produced (Fig. 1). When the
glycosyl composition was analyzed, we found that the samples
with the most negative zeta potential were most likely to test
positive for glucuronic acid in the glycosyl analysis, consistent
with the notion that such samples had higher content of this
negatively charged constituent. We tested whether growth
temperature could also alter the zeta potential of the GalXM
produced. For GalXM from strain cap59, zeta potential mea-
surements were 16.91 	 0.92 at 25°C, 13.09 	 3.34 mV at
30°C, 19.26 	 2.64 at 37°C, and 15.17 	 1.49 mV at 40°C.
For GalXM from strain cap67, zeta potential measurements
were 15.04 	 1.01 at 25°C, 11.43 	 1.23 mV at 30°C,
14.63 	 1.01 at 37°C, and 11.63 	 0.92 mV at 40°C. These
results suggest that growth temperature had as smaller effect
on the GalXM zeta potentials than growth medium (Fig. 1).
Effective diameter and multimodal size distribution analysis
of GalXM. To gain additional insight into the structural rela-
tionship between cap59 and cap67 GalXMs, we determined
average effective diameters and size distributions of PS in dif-
ferent media and at different temperatures using multiangle
light scattering. Although GalXM from both strains was com-
prised of populations of various diameters, it is clear that both
the culture medium and growth temperature could affect the
effective diameter and polydispersity of GalXM preparations.
The effective diameter of GalXM from cap67 in minimal me-
dium could not be determined since GalXM extractions under
these conditions did not yield any polysaccharide. Polydisper-
sity is a measure of the particle size distribution. We observed
variation in GalXM effective diameters for both strains de-
pending on growth medium conditions. This variation was
most apparent for cap59 GalXM. We observed modest shifts
in effective diameters as growth temperature was increased.
The largest diameters were detected at 30°C for both cap59
and cap67 GalXM (Fig. 2 and 3 and Tables 3 and 4). The
dynamic light-scattering parameters of cap59 and cap67
GalXMs derived from cultures grown in peptone and galac-
tose at 30°C were measured as a function of salt concentra-
tion. The results revealed different responses for cap59 and
cap67 GalXM as a function of salt concentration (Fig. 4 and
Table 5).
Antigenic differences between C. neoformans serotype A and
D GalXMs. A polyclonal serum against GalXM was obtained
from mice immunized with a GalXM-Bacillus anthracis protec-
tive antigen (PA) conjugate (9, 10). The polyclonal antibody to
GalXM was slightly reactive with cap59 GalXM and strongly
reactive with cap67 GalXM by ELISA (data not shown). The
immunofluorescence pattern of antibody binding to GalXM in
encapsulated cryptococcal cells is dot- or punctate-like (10).
When we compared different strains, we noted wide discrep-
ancies in the number of dots surrounding individual cells and
TABLE 3. Effects of medium on GalXM size
GalXM type and
condition
Effective
diam
(nm)b
Polydispersityb Size distribution ranges(nm)d
Strain Mediuma
cap59 YPD 783 	 4 0.287 	 0.011 150–200, 250–800,
1,100–1,670
cap67 YPD 526 	 14 0.429 	 0.01 120–185, 975–1630
cap59 Minimal 175 	 4 0.413 	 0.01 50–145, 260–710
cap67 Minimal NAc NA NA
cap59 Sab 657 	 36 0.362 	 0.01 180–512, 1,173–3,315
cap67 Sab 976 	 12 0.203 	 0.01 490–663, 1,300–1,762
cap59 Pep-Gal 592 	 13 0.338 	 0.01 215–300, 1,130–1,710
cap67 Pep-Gal 696 	 58 0.373 	 0.007 109–162, 273–400,
1,300–2,220
a Sab, Sabouraud’s broth; Pep-Gal, peptone supplemented with galactose.
b Error was calculated from 10 measurements of one sample.
c NA, data not available.
d Predominant fragment sizes are given.
TABLE 4. Effects of temperature on GalXM sizea
GalXM type
and condition Effective
diam
(nm)b
Polydispersityb Size distribution ranges(nm)c
Strain Temp(°C)
cap59 25 378 	 15 0.404 	 0.01 144–206, 950–1,360
cap67 25 280 	 6 0.295 	 0.004 130–186, 534–760
cap59 30 592 	 13 0.338 	 0.01 215–300, 1,130–1,710
cap67 30 696 	 58 0.373 	 0.007 109–162, 273–400,
1,300–2,220
cap59 37 346 	 7 0.254 	 0.008 90–100, 207–260
cap67 37 496 	 10 0.284 	 0.01 123–170, 585–880
cap59 40 330 	 15 0.359 	 0.008 49, 178–272, 980–1,500
cap67 40 435 	 9 0.374 	 0.008 150–240, 960–1,520
a Cells were grown in peptone supplemented with galactose.
b Error was calculated from 10 measurements of one sample.
c Predominant fragment sizes are given.
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estimated the reactivity of the polyclonal antibody and/or
amount of GalXM/cell by counting the average number of dots
per cell. We tested eight strains each of serotype A and D and
looked at the percentage of labeled cells. Using this measure-
ment, we found that the percentages of labeling differed be-
tween A and D serotypes (P  0.01) (Fig. 5). Seven strains of
C. gattii (serotypes B and C) were also studied, and none
stained with the polyclonal antibody to serotype D GalXM
(data not shown).
To investigate the dynamics of GalXM production in C.
FIG. 4. Effective diameter and multimodal size distribution of GalXM from strains cap59 and cap67 grown in peptone supplemented with 2%
galactose as a function of salt concentration. GalXM from each strain studied was diluted in distilled water (dH20) or 1 mM, 5 mM, and 10 mM
NaCl. x and y axes are the same as in Fig. 1 and 2.
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neoformans, we studied antibody to GalXM binding as a func-
tion of growth time for strains B3501 (serotype D), 24067
(serotype D), and H99 (serotype A) in 12-h intervals for 2.5
days. The results revealed a sigmoidal pattern in GalXM stain-
ing as a function of time, which paralleled the shape of the C.
neoformans growth curve except that it occurred 12 to 24 h
later (Fig. 6). The highest percentage of GalXM staining was
found in the stationary phase (Fig. 6A, B, and C). To further
quantify GalXM production, we categorized the labeled cells
into four groups depending on their number of fluorescence
dots (Fig. 6D, E, and F). The results revealed a change in
GalXM production with time. Toward the end of log phase at
24 h, the labeled C. neoformans showed a high percentage of
the weakly labeled group, i.e., 1 to 5 dots per cell, indicating
the low GalXM production during the active replication of the
fungal population (Fig. 6D, E, and F). In contrast, in stationary
phase, i.e., at
36 h, the labeled cell possessed a much stronger
labeling pattern, as shown by the increasing number of fluo-
rescence dots with time. Figure 7 shows representative exam-
ples of the cells counted in this assay. Despite these growth
effects on GalXM expression, we note that the quantitative
differences in staining described above were not a consequence
of the kinetics of fungal growth since all studies used cells from
48-h or stationary-phase cell cultures.
DISCUSSION
Earlier studies suggested that GalXM was structurally
heterogeneous since its galactose, mannose, and xylose com-
ponents could potentially be linked in 15 different ways (17).
The biochemical complexity of that data suggested that the
purified GalXM fractions could be part of a composite of
several closely related antigens (17). Using proton NMR in
an earlier study, we also found subtle differences among the
different GalXM molecules (10). These data in turn implied
that fine structural differences in the GalXM molecule could
translate into antigenic variability (10). Here, we explore
these differences using composition analysis, molecular
weight, zeta potential, polydispersity measurements, and im-
munofluorescence.
GalXM derived from the acapsular C. neoformans var. neo-
formans and C. neoformans var. grubii strains each contained
galactose, mannose, and xylose but differed in the molar per-
centage of these components. Different media resulted in the
production of GalXMs with different structural and physical
properties, suggesting that studies of GalXM function should
carefully control for nutritional conditions during culture
growth. In contrast, the GalXM structure was more stable with
respect to growth temperature. We also confirmed the pres-
ence of glucuronic acid in our GalXM preparations, as re-
ported in a recent study (16). Since glucuronic acid is difficult
to measure accurately relative to the other monosaccharide
components, we used zeta potential measurements as a surro-
gate measure for the presence of negatively charged constitu-
ents in GalXM. Zeta potential measurements revealed a neg-
ative charge for all GalXM preparations from both cap67 and
cap59 under different medium conditions. GalXM samples
with the highest negative zeta potential were more likely to
show the presence of glucuronic acid. These results, together
with the prior report of glucuronic acid in GalXM, establish
that this polysaccharide, like GXM, is negatively charged.
We explored the structural relationship between GalXM
derived from cap59 (serotype A) and cap67 (serotype D).
Static light-scattering measurements revealed that the average
molecular mass of the GalXM from variety C. neoformans var.
grubii was 8-fold larger than that of C. neoformans var. neo-
formans. From the Rg and Mw we calculated the mass density,
and the results revealed that cap59 GalXM was 4-fold denser
than the cap67 GalXM. These differences might also suggest
differences in internal structure conformations (or shape fac-
tor) between both PS. Dynamic light scattering revealed that
GalXM from both strains was comprised of a population of
various diameters and that the relative distribution of diame-
ters and extent of polydispersity were affected by both the
growth medium and temperature. The ionic strength also af-
fected the measured polydispersity, suggesting that GalXM
conformational variability is a function of anion and cation
concentration. In this regard, the effective diameters in cap59
FIG. 5. Percentage of cells labeled by polyclonal antibody to
GalXM among eight strains of serotypes A and D after 48 h of culture
growth. Serotype D strains show a higher percentage of labeled cells
than serotype A strains (P  0.01).
TABLE 5. Effects of NaCl on GalXM sizea
Diluent and
GalXM source
strainb
Effective
diam (nm)c Polydispersity
c Size distribution
ranges (nm)d
dH20
cap59 319 	 2 0.239 	 0.008 151–203, 486–651
cap67 630 	 33 0.356 	 0.008 220–319, 1,518–2,190
1 mM NaCl
cap59 414 	 5 0.262 	 0.017 146–181, 521–740
cap67 936 	 69 0.373 	 0.019 323–483, 2,186–3,268
5 mM NaCl
cap59 409 	 5 0.266 	 0.006 182–269, 645–920
cap67 834 	 8 0.392 	 0.011 269–409, 2,188–3,696
10 mM NaCl
cap59 401 	 4 0.291 	 0.013 171–217, 523–702
cap67 1081 	 141 0.552 	 0.142 277–459, 2,809–4,646
a Cells were grown in peptone supplemented with galactose.
b dH2O, distilled water.
c Error was calculated from 10 measurements of one sample.
d Predominant fragment sizes are given.
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become smaller as salt concentration is increased while in
cap67 the effective diameters increased. This difference in re-
sponse may reflect differences in charge positioning in the
GalXMs of these strains, which in turn would imply differences
in primary structural arrangements of the monosaccharide
constituents.
We note that the mass of the cap67 GalXM reported here is
larger than that reported in our prior study (21). Given all the
structural variability uncovered by the current study, we at-
tribute that difference to the culture growth conditions used to
prepare GalXM in the prior and current study. In the earlier
study cap67 cultures were grown in Sabouraud’s dextrose
broth; in this study we used peptone supplemented with 2%
galactose since we found that this medium gave a higher yield
of purified GalXM. Lastly, we note differences in the sign of
the second virial coefficient value for GalXMs from cap59 and
cap67 measured by static light scattering. Positive and negative
values for the second virial coefficient reflect globally repulsive
and attractive intermolecular interactions, respectively, provid-
ing an additional parameter for differences between the
GalXMs produced by these strains.
In considering the biological implications of these results, it
is important to note one potential limitation of the work de-
scribed here, namely, reliance on GalXM derived from acap-
sular strains. This reliance on using GalXM from acapsular
strains is necessitated by the fact that there are currently no
methodologies that completely separate GalXM from GXM,
especially given data that these two polysaccharides can inter-
act (12). Since culture supernatants from encapsulated strains
contain copious amounts of GXM, all structural studies of
GalXM have relied on material from acapsular strains. How-
ever, this introduces a potential systematic problem for
GalXM studies because the phenotype of acapsular strains like
cap67 and cap59 may reflect a secretion defect (15). Hence, it
is conceivable that the GalXM from acapsular strains has
structural differences from that of wild-type strains. Currently,
there is no methodology to ascertain whether this concern is
real since attempts to develop better serological reagents in the
form of monoclonal antibodies (MAbs) have not proved suc-
cessful, and we lack reagents to compare the GalXM structures
in capsular and their acapsular mutants (10).
Given the potential limitations inherent in working with
acapsular strains noted above and the paucity of well-charac-
terized acapsular mutants expressing the same genetic defect
such as strains cap67 and cap59, we investigated GalXM vari-
ability in wild-type strains by evaluating their reactivity for
immune serum reactive with GalXM. All serotype A and D
strains reacted with immune serum generated against GalXM
FIG. 6. GalXM immunofluorescence staining was dependent on growth phase in C. neoformans. Strains B3501 (serotype D) (A), 24067
(serotype D) (B), and H99 (serotype A) (C) each showed comparable patterns in both growth kinetics and GalXM labeling as a function of culture
time. Maximum GalXM staining occurred in the stationary phase. Panels D, E, and F show the frequency of dots per cell and as a function of time
for strains B3501, 24067, and H99, respectively. Fig. 7 shows representative examples of the cells counted in this assay.
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from serotype D, with serotype D strains producing stronger
reactivity. Serum reactivity with cryptococcal cells was a func-
tion of growth phase for both serotype A and D strains, and
was most prominent in stationary-phase cells. In contrast, no
immunoreactivity was observed with any of the C. gattii strains.
We interpret these results as indicating that GalXMs from
serotypes A and D share antigenic determinants that presum-
ably reflect the presence of common structural motifs not
found in C. gattii strains. Hence, the serological studies imply
quantitative differences in GalXM epitope content between A
and D strains that could reflect differences in GalXM amount
and/or chemical structure.
In summary, we report large intra- and interstrain variability
in the structure, serological reactivity, and physical properties
of GalXM as a function of growth conditions. One practical
consequence of these results is that experiments comparing
GalXM structural properties must take into account growth
conditions. Given this structural variability, it is possible that
GalXM made in vivo is structurally different from that made in
culture. In fact, it is conceivable that interstrain and growth-
related differences in GalXM structure are responsible for
discrepant results observed regarding serological cross-reactiv-
ity of the polysaccharide with other antigens (7, 8). Given that
GalXM has now been associated with profound immunological
derangements (26, 27, 30), it is likely that this polysaccharide
makes a contribution to the virulence composition of C. neo-
formans (9, 20, 23). Since the biological properties of GalXM
must reflect its structure, we suspect that structural variability
could translate into variable effects in host damaging effects.
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